Colin O. Wu

发表

Donor KIR Genes 2DL5A, 2DS1 and 3DS1 are associated with a reduced rate of leukemia relapse after HLA-identical sibling stem cell transplantation for acute myeloid leukemia but not other hematologic malignancies.

Marcela R. Uribe, S. Adams, A. Barrett, 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Constitutional telomerase mutations are genetic risk factors for cirrhosis

S. Chanock, N. Young, M. Zago, 2011, Hepatology.

Long-term outcome of pediatric patients with severe aplastic anemia treated with antithymocyte globulin and cyclosporine.

N. Young, P. Scheinberg, Colin O. Wu, 2007, The Journal of pediatrics.

Eltrombopag monotherapy can improve hematopoiesis in patients with low to intermediate risk-1 myelodysplastic syndrome.

Xingmin Feng, S. Kajigaya, N. Young, 2020, Haematologica.

Long-term outcomes in myelodysplastic syndrome patients treated with alemtuzumab.

N. Young, Catherine Lai, C. Hourigan, 2019, Blood Advances.

Treatment optimization and genomic outcomes in refractory severe aplastic anemia treated with eltrombopag.

M. Desierto, N. Young, P. Scheinberg, 2019, Blood.

Treatment of severe aplastic anaemia with combined immunosuppression: anti‐thymocyte globulin, ciclosporin and mycophenolate mofetil

N. Young, P. Scheinberg, Colin O. Wu, 2006, British journal of haematology.

Clonal hematopoiesis is not significantly associated with COVID-19 disease severity

F. Rieux-Laucat, L. Notarangelo, K. Dobbs, 2022, Blood.

Donor lymphocyte count and thymic activity predict lymphocyte recovery and outcomes after matched-sibling hematopoietic stem cell transplant

J. Melenhorst, A. Barrett, N. Hensel, 2013, Haematologica.

Predicting response of severe aplastic anemia to immunosuppression combined with eltrombopag

Xingmin Feng, N. Young, Colin O. Wu, 2021, Haematologica.

Predictors of clonal evolution and myeloid neoplasia following immunosuppressive therapy in severe aplastic anemia

K. Calvo, C. Dunbar, Fernanda Gutierrez-Rodrigues, 2022, Leukemia.

Increased soluble urokinase plasminogen activator receptor (suPAR) is associated with thrombosis and inhibition of plasmin generation in paroxysmal nocturnal hemoglobinuria (PNH) patients.

N. Young, P. Scheinberg, E. Sloand, 2008, Experimental hematology.

HLA associations, somatic loss of HLA expression, and clinical outcomes in immune aplastic anemia.

Xingmin Feng, S. Kajigaya, S. Adams, 2021, Blood.

Horse versus rabbit antithymocyte globulin in acquired aplastic anemia.

N. Young, P. Scheinberg, A. Biancotto, 2011, The New England journal of medicine.

aplastic anemia that can be sustained on discontinuation of drug Eltrombopag restores trilineage hematopoiesis in refractory severe

B. Dumitriu, P. Scheinberg, M. Bevans, 2014 .

Alemtuzumab Is Safe and Associated With High Response Rates In Selected Patients With Myelodysplastic Syndrome

N. Young, C. Hourigan, P. Scheinberg, 2013 .

Cytokine signature profiles in acquired aplastic anemia and myelodysplastic syndromes

J. P. McCoy, R. Ganetzky, Xingmin Feng, 2011, Haematologica.

Prediction and prevention of transplant-related mortality from pulmonary causes after total body irradiation and allogeneic stem cell transplantation.

S. Solomon, A. Barrett, R. Childs, 2005, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Long-term follow-up of patients with moderate aplastic anemia and pure red cell aplasia treated with daclizumab

N. Young, P. Scheinberg, J. Maciejewski, 2010, Haematologica.

Treatment of severe aplastic anemia with a combination of horse antithymocyte globulin and cyclosporine, with or without sirolimus: a prospective randomized study

N. Young, P. Scheinberg, E. Sloand, 2009, Haematologica.

Predicting response to immunosuppressive therapy and survival in severe aplastic anaemia

N. Young, P. Scheinberg, Colin O. Wu, 2009, British journal of haematology.

Immunosuppressive Treatment Is Associated with Durable Responses and a Survival Advantage in Younger Patients with int-1 Myelodysplastic Syndrome.

P. Greenberg, N. Young, E. Sloand, 2005 .

A Randomized Trial of Horse Versus Rabbit Antithymocyte Globulin In Severe Acquired Aplastic Anemia

N. Young, P. Scheinberg, E. Sloand, 2010 .

Clinical outcomes and immune responses to SARS‐CoV‐2 vaccination in severe aplastic anaemia

R. Koup, A. McDermott, Madhu S. Prabhakaran, 2022, British journal of haematology.

Long Term Outcome of Pediatric Patients with Severe Aplastic Anemia Treated with Anti-Thymocyte Globulin and Cyclosporine.

N. Young, P. Scheinberg, Colin O. Wu, 2007 .

Moderate-dose cyclophosphamide for severe aplastic anemia has significant toxicity and does not prevent relapse and clonal evolution.

B. Dumitriu, N. Young, P. Scheinberg, 2014, Blood.

Danazol Treatment for Telomere Diseases.

B. Dumitriu, Jianhua Yao, N. Young, 2016, The New England journal of medicine.

No impact of lentiviral transduction on hematopoietic stem/progenitor cell telomere length or gene expression in the rhesus macaque model.

B. Dumitriu, N. Young, R. Calado, 2014, Molecular therapy : the journal of the American Society of Gene Therapy.

Decreased infection-related mortality and improved survival in severe aplastic anemia in the past two decades.

N. Young, P. Scheinberg, T. Walsh, 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Granulocyte transfusions in severe aplastic anemia: an eleven-year experience

N. Young, P. Scheinberg, T. Walsh, 2009, Haematologica.

Alemtuzumab (Campath) Monotherapy for Severe Aplastic Anemia.

N. Young, P. Scheinberg, E. Sloand, 2010 .

Alemtuzumab treatment of intermediate-1 myelodysplasia patients is associated with sustained improvement in blood counts and cytogenetic remissions.

N. Young, P. Scheinberg, A. Barrett, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Eltrombopag Added to Standard Immunosuppression for Aplastic Anemia

B. Dumitriu, Xingmin Feng, M. Desierto, 2017, The New England journal of medicine.

Eltrombopag and improved hematopoiesis in refractory aplastic anemia.

B. Dumitriu, Xingmin Feng, N. Young, 2012, The New England journal of medicine.

Somatic Mutations and Clonal Hematopoiesis in Aplastic Anemia.

S. Miyano, B. Dumitriu, Y. Shiraishi, 2015, The New England journal of medicine.

Differential diagnosis of bone marrow failure syndromes guided by machine learning.

Christopher M. Siwy, Ronald M. Summers, Paul Liu, 2022, Blood.

Association of telomere length of peripheral blood leukocytes with hematopoietic relapse, malignant transformation, and survival in severe aplastic anemia.

N. Young, P. Scheinberg, R. Calado, 2010, JAMA.

Alemtuzumab in T-cell large granular lymphocytic leukaemia: a phase 2 study

M. Raffeld, B. Dumitriu, Xingmin Feng, 2015, The Lancet. Haematology.

In vivo effects of horse and rabbit antithymocyte globulin in patients with severe aplastic anemia

J. P. McCoy, S. Donaldson, Kazuya Sato, 2014, Haematologica.

Distinct EBV and CMV reactivation patterns following antibody-based immunosuppressive regimens in patients with severe aplastic anemia.

S. Fischer, N. Young, P. Scheinberg, 2006, Blood.

Activity of alemtuzumab monotherapy in treatment-naive, relapsed, and refractory severe acquired aplastic anemia.

N. Young, P. Scheinberg, Colin O. Wu, 2012, Blood.

Eltrombopag added to immunosuppression for children with treatment‐naïve severe aplastic anaemia

N. Young, Fernanda Gutierrez-Rodrigues, D. Townsley, 2021, British journal of haematology.

Eltrombopag for patients with moderate aplastic anemia or uni-lineage cytopenias.

B. Dumitriu, N. Young, M. Albitar, 2020, Blood advances.

Clonal tracking of rhesus macaque hematopoiesis highlights a distinct lineage origin for natural killer cells.

Chuanfeng Wu, C. Dunbar, R. Donahue, 2014, Cell stem cell.

Pretransplant pulmonary function tests predict risk of mortality following fractionated total body irradiation and allogeneic peripheral blood stem cell transplant.

R. Altemus, H. Ning, P. Guion, 2006, International journal of radiation oncology, biology, physics.

T-cell immune responses to Wilms tumor 1 protein in myelodysplasia responsive to immunosuppressive therapy.

D. Douek, J. Brenchley, N. Young, 2011, Blood.

Factors affecting response and survival in patients with myelodysplasia treated with immunosuppressive therapy.

John Barrett, Neal Young, Peter Greenberg, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Alemtuzumab in T-cell large granular lymphocytic leukaemia: interim results from a single-arm, open-label, phase 2 study.

M. Raffeld, B. Dumitriu, Xingmin Feng, 2016, The Lancet. Haematology.

Long-term outcomes in severe aplastic anemia patients treated with immunosuppression and eltrombopag: a phase 2 study.

N. Young, Fernanda Gutierrez-Rodrigues, Colin O. Wu, 2021, Blood.

Prolonged cyclosporine administration after antithymocyte globulin delays but does not prevent relapse in severe aplastic anemia

N. Young, P. Scheinberg, Colin O. Wu, 2014, American journal of hematology.

Horse antithymocyte globulin as salvage therapy after rabbit antithymocyte globulin for severe aplastic anemia

B. Dumitriu, N. Young, P. Scheinberg, 2014, American journal of hematology.

Telomere Length of Peripheral Blood Leukocytes Predicts Relapse and Clonal Evolution after Immunosuppressive Therapy in Severe Aplastic Anemia

N. Young, P. Scheinberg, R. Calado, 2008 .

Clonal Hematopoiesis in Vexas Syndrome

D. Kastner, K. Calvo, T. Lasho, 2022, Blood.

Circulating Cytokine Profiles of Patients with Acquired Aplastic Anemia and Myelodysplastic Syndrome

J. P. McCoy, R. Ganetzky, Xingmin Feng, 2008 .

Cyclosporine Taper Does Not Prevent Relapse in Severe Aplastic Anemia

N. Young, P. Scheinberg, Colin O. Wu, 2011 .

Treatment of Severe Aplastic Anemia with Combined Immunosuppression: Antithymocyte Globulin (ATG), Cyclosporine A (CSA), and Mycophenolate Mofetil (MMF).

N. Young, P. Scheinberg, Colin O. Wu, 2005 .

A phenotypic risk score for predicting mortality in sickle cell disease

C. Wu, S. Thein, V. Sachdev, 2021, British journal of haematology.